Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a research report sent to investors on Saturday morning. They currently have $7.75 target price on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other brokerages have also weighed in on KURA. Cann restated a buy rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Monday, May 15th. Citigroup Inc. set a $13.00 price objective on Kura Oncology and gave the company a buy rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated an outperform rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Wednesday, June 28th. Cowen and Company began coverage on Kura Oncology in a report on Thursday, September 7th. They issued an outperform rating on the stock. Finally, Leerink Swann reiterated an outperform rating and set a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $14.15.
Shares of Kura Oncology (KURA) opened at 11.10 on Friday. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $13.80. The company has a 50-day moving average of $8.04 and a 200 day moving average of $8.77. The company’s market cap is $221.87 million.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. On average, analysts anticipate that Kura Oncology will post ($1.53) earnings per share for the current year.
Several large investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. increased its position in shares of Kura Oncology by 14.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after purchasing an additional 1,600 shares during the last quarter. Nationwide Fund Advisors grew its position in Kura Oncology by 66.2% in the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after acquiring an additional 10,258 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Kura Oncology in the 2nd quarter valued at about $102,000. Segantii Capital Management Ltd acquired a new position in Kura Oncology in the 1st quarter valued at about $120,000. Finally, Rhumbline Advisers acquired a new position in Kura Oncology in the 2nd quarter valued at about $131,000. 39.07% of the stock is owned by hedge funds and other institutional investors.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.